MA54469A - Anticorps anti-il-27 et leurs utilisations - Google Patents
Anticorps anti-il-27 et leurs utilisationsInfo
- Publication number
- MA54469A MA54469A MA054469A MA54469A MA54469A MA 54469 A MA54469 A MA 54469A MA 054469 A MA054469 A MA 054469A MA 54469 A MA54469 A MA 54469A MA 54469 A MA54469 A MA 54469A
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862779341P | 2018-12-13 | 2018-12-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA54469A true MA54469A (fr) | 2021-10-20 |
Family
ID=71075792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA054469A MA54469A (fr) | 2018-12-13 | 2019-09-25 | Anticorps anti-il-27 et leurs utilisations |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220259299A1 (fr) |
EP (1) | EP3894440A4 (fr) |
JP (1) | JP2022514499A (fr) |
KR (1) | KR20210104064A (fr) |
CN (1) | CN113544151A (fr) |
AU (1) | AU2019399474A1 (fr) |
BR (1) | BR112021011393A2 (fr) |
CA (1) | CA3121420A1 (fr) |
EA (1) | EA202191666A1 (fr) |
IL (1) | IL283875A (fr) |
MA (1) | MA54469A (fr) |
MX (1) | MX2021006980A (fr) |
SG (1) | SG11202105161YA (fr) |
WO (1) | WO2020123011A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220066346A (ko) * | 2019-09-25 | 2022-05-24 | 서피스 온콜로지, 인크. | 항-il-27 항체 및 이의 용도 |
WO2023230116A1 (fr) * | 2022-05-25 | 2023-11-30 | Surface Oncology, Inc. | Utilisation d'anticorps anti-il-27 |
WO2023230128A1 (fr) * | 2022-05-25 | 2023-11-30 | Surface Oncology, Inc. | Utilisation d'anticorps anti-il-27 |
WO2024028773A1 (fr) * | 2022-08-03 | 2024-02-08 | Pfizer Inc. | Anticorps anti-il27r et leurs méthodes d'utilisation |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050214296A1 (en) * | 2004-02-17 | 2005-09-29 | Schering Corporation | Methods of modulating cytokine activity; related reagents |
AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
WO2011133931A1 (fr) * | 2010-04-22 | 2011-10-27 | Genentech, Inc. | Utilisation d'antagonistes d'il-27 pour traiter une maladie intestinale inflammatoire |
AU2012205384B2 (en) * | 2011-01-14 | 2015-09-10 | Five Prime Therapeutics, Inc. | IL-27 antagonists for treating inflammatory diseases |
US20230192896A1 (en) * | 2016-11-23 | 2023-06-22 | Bioverativ Therapeutics Inc. | Bispecific antibodies binding to coagulation factor ix and coagulation factor x |
JP7328983B2 (ja) * | 2018-03-22 | 2023-08-17 | サーフィス オンコロジー インコーポレイテッド | 抗il-27抗体及びその使用 |
-
2019
- 2019-09-25 CN CN201980082814.5A patent/CN113544151A/zh active Pending
- 2019-09-25 SG SG11202105161YA patent/SG11202105161YA/en unknown
- 2019-09-25 EA EA202191666A patent/EA202191666A1/ru unknown
- 2019-09-25 AU AU2019399474A patent/AU2019399474A1/en active Pending
- 2019-09-25 KR KR1020217019243A patent/KR20210104064A/ko active Search and Examination
- 2019-09-25 WO PCT/US2019/053036 patent/WO2020123011A1/fr unknown
- 2019-09-25 CA CA3121420A patent/CA3121420A1/fr active Pending
- 2019-09-25 JP JP2021533517A patent/JP2022514499A/ja active Pending
- 2019-09-25 MA MA054469A patent/MA54469A/fr unknown
- 2019-09-25 US US17/413,269 patent/US20220259299A1/en active Pending
- 2019-09-25 BR BR112021011393-2A patent/BR112021011393A2/pt unknown
- 2019-09-25 EP EP19895768.0A patent/EP3894440A4/fr active Pending
- 2019-09-25 MX MX2021006980A patent/MX2021006980A/es unknown
-
2021
- 2021-06-10 IL IL283875A patent/IL283875A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2019399474A1 (en) | 2021-06-03 |
MX2021006980A (es) | 2021-07-15 |
KR20210104064A (ko) | 2021-08-24 |
EA202191666A1 (ru) | 2022-03-14 |
CN113544151A (zh) | 2021-10-22 |
CA3121420A1 (fr) | 2020-06-18 |
EP3894440A1 (fr) | 2021-10-20 |
JP2022514499A (ja) | 2022-02-14 |
US20220259299A1 (en) | 2022-08-18 |
BR112021011393A2 (pt) | 2021-08-31 |
EP3894440A4 (fr) | 2022-09-07 |
WO2020123011A1 (fr) | 2020-06-18 |
SG11202105161YA (en) | 2021-06-29 |
IL283875A (en) | 2021-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52773A (fr) | Anticorps anti-cd3 et leurs utilisations | |
MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
MA49683A (fr) | Anticorps anti-cd8 et leurs utilisations | |
MA52949A (fr) | Anticorps anti-pd-1 et leurs utilisations | |
MA49687A (fr) | Anticorps anti-ctla-4 et leurs utilisations | |
MA46708A (fr) | Anticorps anti-pd1 et leurs utilisations | |
MA45235A (fr) | Anticorps anti-c5 et leurs utilisations | |
MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
MA52414A (fr) | Anticorps agonistes de pd-1 et leurs utilisations | |
MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
MA53168A (fr) | Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations | |
MA53184A (fr) | Anticorps anti-ox40 et leurs utilisations | |
MA50144A (fr) | Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées | |
MA52970A (fr) | Anticorps anti-psma x anti-cd28 bispécifiques et leurs utilisations | |
MA50397A (fr) | Anticorps anti-tau et leurs utilisations | |
MA50618A (fr) | Polyrhérapies et leurs utilisations | |
MA54539A (fr) | Anticorps anti-muc16 x anti-cd28 bispécifiques et leurs utilisations | |
MA52426A (fr) | Conjugués d'il-15 et leurs utilisations | |
MA42935A (fr) | Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations | |
MA52771A (fr) | Anticorps anti-cd33, anticorps bispécifiques anti-cd33/anti-cd3 et leurs utilisations | |
MA45233A (fr) | Anticorps anti-gitr et leurs utilisations | |
MA46704A (fr) | Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations | |
MA43567A (fr) | Anticorps pacap et leurs utilisations | |
MA52094A (fr) | Anticorps anti-il-27 et leurs utilisations |